ascopubs.org

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB) Patients were ...
FierceBiotech

Medidata and Cogstate combine data tools and cognitive assessments to improve CNS trials

Clinical research and health tech companies Medidata and Cogstate are joining forces to speed up trials and improve outcomes measurement across diseases of the central nervous system, the partners ...
ascopubs.org

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase ...
Medical Design & Outsourcing

Three ways that decentralized trial design strengthens the regulatory case for CNS devices

Decentralized trials help developers of central nervous system treatments and devices address shifting regulatory barriers.
FiercePharma

Elevating Data Quality in CNS Trials Through Thoughtful Use of eCOA

Central nervous system (CNS) clinical trials are among the most scientifically complex and operationally demanding in life sciences. The need to evaluate nuanced cognitive, behavioral, and emotional ...